Taken together, in vivo experiments indicated that the redox sensitivity liposomes with bone and CD44 dual targeting enabled a specific and efficient delivery of the AraC to the leukemia cells, which could kill the leukemia cells in mice. The gene discussed is CD44; the disease is leukemia.